A Whirlwind of Change in Lung Cancer

Meir Rinde
Published: Tuesday, May 22, 2018
Corey Langer, MD

Corey Langer, MD
Less than 3 years after the first checkpoint blockade immunotherapies were introduced for non–small cell lung cancer (NSCLC), the treatment paradigm is poised for dramatic changes in frontline care for patients with metastatic disease.


Table. Key Findings in Frontline Lung Cancer Studies

Pembrolizumab Findings

In the KEYNOTE-189 trial, investigators found that pembrolizumab with pemetrexed (Alimta) and either cisplatin or carboplatin showed a much greater benefit than chemotherapy alone, reducing the risk of death by over 50% in patients with nonsquamous NSCLC without EGFR or ALK mutations.1,2 At a median follow-up of 10.5 months, the estimated 12-month overall survival (OS) rate was 69.2% (95% CI, 64.1%-73.8%) in the pembrolizumab arm compared with 49.4% (95% CI, 42.1%-56.2%) in the control group (HR, 0.49; 95% CI, 0.38-0.64; P <.001).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication